2020

Availability of the Q4 2020 Memorandum for modelling purposes

Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly

Sanofi to resume dosing in fitusiran clinical studies in the U.S.

Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities

Sanofi and Kiadis satisfy competition condition related to the tender offer

Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis

Update on the intended offer by Sanofi for Kiadis

European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older

European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older

Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia

FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease

FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease

New clinical and health-related quality of life data in multiple myeloma and rare blood disorders to be presented at ASH 2020

Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products

Sanofi offers to acquire Kiadis for €308 million

European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)

Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER

Safety and efficacy of Dupixent® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis further reinforced by new data analyses presented at EADV

Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology

Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine

Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease

Sanofi completes Principia Biopharma Inc. acquisition

Availability of the Q3 2020 Memorandum for modelling purposes

CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older

Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

CHMP recommends approval of MenQuadfi® for active immunization of individuals from the age of 12 months and older against invasive meningococcal ACWY disease

Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union

Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 

Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation

FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis

New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A

Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma

Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.

Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.

Sanofi to acquire Principia Biopharma

Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine

Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine

Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial

Online availability of Sanofi’s half-year financial report for 2020

Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation

Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine

Availability of the Pre-quarterly Results Communication

Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients

Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients

Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas

Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors 

Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis

Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease

Sanofi invests to make France its world class center of excellence in vaccine research and production

Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases

Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease

Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan

Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma

European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma

Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline

Sanofi announces closing of Regeneron stock sale

Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time

Sanofi names new leaders to Executive Committee

Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director

Sanofi announces pricing of Regeneron stock offering

Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration

Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints

Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event

FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease

Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma

Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma

Sanofi: Annual General Meeting of April 28, 2020

Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival

Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients

FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination

Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis

Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis

Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

COVID-19:  Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries 

Sanofi finalizes Praluent® (alirocumab) restructuring with Regeneron

Sanofi successfully prices taps on outstanding bond issues for EUR 500 million

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi: Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years

Sanofi: Information on Sanofi’s Shareholder General Meeting of Tuesday, April 28, 2020

Sanofi: First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19

Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma

Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19

Sanofi successfully prices EUR 1.5 billion of bond issue

Sanofi : Filing of the 2019 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors

Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

Sanofi delivers strong 2019 business EPS growth of 6.8% at CER

Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis

Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency

Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

Sanofi : Sanofi Completes Acquisition of Synthorx, Inc.

Sanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx

Sanofi : Availability of the Pre-quarterly Results Communication